---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000029"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:42:57.827715+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023

## Summary
- Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.
- Cash and equivalents $3.7M at Dec 31, 2024; plus $5M from JuvVentures in Jan 2025, projected to fund through Q2 2025.
- R&D expense increased $5.1M to $7.5M, driven by SER-252 development and higher headcount.
- Sold UniverXome subsidiary in Dec 2024, eliminating $11.2M debt; $10M equity financing from JuvVentures secured.
- Appointed Karen J. Wilson and Dr. Jay Venkatesan to board; targeting first patient in Phase 1b trial for SER-252 in Q4 2025.

## SEC filing metadata
- accession: 0001708599-25-000029
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/0001708599-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/ser-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000029
- JSON: https://secwatch.observer/filing/0001708599-25-000029.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.